Press

MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

Aug 3 • 3 min read

Quick Take: MindMed has joined Digital Medicine Society, an organization dedicated to improving medical practices and outcomes through technology. MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announced today that it will participate in and financially support the Digital Medicine Society’s (DiMe) Digital Health Measurement Collaborative Community (DATAcc), an effort…

Wesana Health Announces Listing on OTCQB Venture Market

Aug 2 • 2 min read

Quick Take: Wesana Health has recieved approval from the OTC Markets to begin trading on the OTCQB. Wesana Health Holdings Inc. (CSE: WESA), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, is pleased to…

Bionomics Announces Plans to Conduct U.S. Initial Public Offering

Aug 2 • 3 min read

Quick Take: Bionomics has revealed its plan to conduct a registered IPO of American Depository Shares and a concurrent listing on Nasdaq. Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stagebiopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the…

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

Jul 30 • 3 min read

Nova Mentis Life Science Corp. (CSE: NOVA),a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announced it has filed a U.S. provisional patent application for a proprietary manufacturing process for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin. “NOVA is developing a novel, proprietary…

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

Jul 30 • 4 min read

Entheon Biomedical Corp. (CSE: ENBI) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual’s response to hallucinogenic and psychoactive drugs. Further to the Company’s…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436